Catheter tip

The integration of hydrolysis inhibitors in catheter tips with tungsten-containing compounds and ester/amide bonds addresses the issue of resin degradation during storage, maintaining the catheter's functionality by suppressing hydrolysis and maintaining resin integrity.

WO2024237091A1PCT designated stage expired Publication Date: 2024-11-21TERUMO KK
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016709
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-04-30
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Catheter tips coated with tungsten for X-ray opacity are prone to resin deterioration during long-term storage due to hydrolysis of ester and amide bonds when exposed to tungsten-containing compounds, leading to degradation and reduced effectiveness.

Method used

Incorporating a hydrolysis inhibitor, such as a carbodiimide group-containing compound, into the resin with ester and amide bonds and tungsten-containing compounds to suppress hydrolysis and maintain resin integrity over time.

Benefits of technology

The use of hydrolysis inhibitors effectively reduces resin deterioration, ensuring the catheter tip remains functional and effective even after prolonged storage by preventing acidic conditions and subsequent hydrolysis of ester and amide bonds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024016709_21112024_PF_FP_ABST
    Figure JP2024016709_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a catheter which is less likely to deteriorate even when stored for a long period of time. A catheter tip according to the present invention includes a resin having an ester bond and / or an amide bond, a tungsten-containing compound, and a hydrolysis inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

Catheter Tip

[0001] The present invention relates to a catheter tip.

[0002] When treating or diagnosing a stenosis, a catheter is used to insert a medical device into a living body and guide it to the target site. To accurately determine the position of the catheter tip when inserting the catheter into a living body, the tip of the catheter usually contains a radiopaque material that enables detection by X-ray. For example, metallic tungsten powder is known as an excellent radiopaque material and is used as a material for the catheter tip (see, for example, Patent Document 1).

[0003] U.S. Pat. No. 5,584,821

[0004] Catheters are not always used immediately, but may be stored for long periods before use. Catheter tips are usually made of resin for their moldability and flexibility, but if tungsten is added to the catheter tip as an X-ray opaque material, there is a risk that the resin may deteriorate.

[0005] Therefore, an object of the present invention is to provide a catheter tip in which the resin is less likely to deteriorate even when stored for a long period of time, and a catheter including the catheter tip.

[0006] A catheter tip according to one embodiment of the present invention has the following configuration: (1) A catheter tip comprising a resin having an ester bond and / or an amide bond, a tungsten-containing compound, and a hydrolysis inhibitor. (2) The catheter tip according to (1), in which the hydrolysis inhibitor is a carbodiimide group-containing compound. (3) The catheter tip according to (1) or (2), in which the content of the tungsten-containing compound is 10 to 90 mass% with respect to the total amount of the resin and the tungsten-containing compound. (4) The catheter tip according to any one of (1) to (3), in which the resin having an ester bond and / or an amide bond comprises a polyamide resin. (5) The catheter tip according to any one of (1) to (4), in which the tungsten-containing compound is dispersed as particles within the resin. (6) A catheter comprising the catheter tip according to any one of (1) to (5).

[0007] 1 is a diagram showing the overall configuration of a catheter, and FIG. 2 is a schematic cross-sectional view of the vicinity of the junction between the catheter tip and the catheter main body.

[0008] The present invention is a catheter tip comprising a resin having an ester bond and / or an amide bond, a tungsten-containing compound, and a hydrolysis inhibitor.

[0009] The catheter tip of the present invention and the catheter including the same reduce the risk of resin deterioration even when stored for a long period of time.

[0010] Tungsten-containing compounds are usually used in combination with resins. The present inventors speculated that the cause of resin deterioration during long-term storage is hydrolysis of ester bonds and / or amide bonds in the presence of a tungsten-containing compound. Based on this speculation, the inventors conducted research and found that the use of a hydrolysis inhibitor in combination with a tungsten-containing compound can suppress the deterioration of resins over time, leading to the completion of the present invention.

[0011] The mechanism by which such an effect is produced is presumed to be as follows: Note that the following mechanism does not in any way limit the technical scope of the present invention.

[0012] Metallic tungsten is oxidized by oxygen in the air or during the manufacturing process, as shown in the formula below, to form metallic tungsten (W) and a very small amount of tungsten oxide (WO 3 ) oxidation state is mixed. 3 When it comes into contact with water, it undergoes a hydration reaction to become tungstic acid, which contributes to the release of acidic hydrogen ions.

[0013]

[0014] The presence of the acidic hydrogen ions causes the system to lean toward acidic conditions, i.e., the pH value decreases. In fact, 1 g of pellet-shaped resin (the resin used in the examples, Table 1, Resin only (without tungsten) below), 1 g of a sample of Comparative Example 1 (resin + tungsten powder) after one week of high temperature and high humidity stress (Table 1, Resin + Tungsten (After One Week of High Temperature and High Humidity Stress) below), and 1 g of a sample of Comparative Example 1 after one week of high temperature and high humidity stress in a sealed state (Table 1, Resin + Tungsten (After One Week of High Temperature and High Humidity Stress in a Sealed State) below) were each added to 5 mL of RO water, stirred, and allowed to stand at room temperature for 24 hours. The pH was measured using a pH meter (AS ONE Corporation AS600, 25°C). As shown in Table 1 below, the pH value of the sample after one week of high temperature and high humidity stress was lower than that of the sample of resin only (without tungsten).

[0015]

[0016] Under acidic conditions, ester and / or amide bond sites in the resin undergo hydrolysis. As the hydrolysis proceeds, the terminal carboxyl groups of the decomposition products act as carboxylic acids, accelerating the hydrolysis reaction rate.

[0017] Table 2 below shows the results of measuring the molecular weight (in PMMA terms) using GPC for the sample of Comparative Example 1 ((1) sample before loading) and the sample ((2) loaded sample) that was left in a high-temperature, high-humidity environment for a certain period of time.

[0018]

[0019] These results indicate that in the presence of a tungsten-containing compound, the resin is decomposed into smaller molecules due to high temperature and humidity. This decomposition of the resin is thought to be due to hydrolysis of the resin.

[0020] Such hydrolysis may progress gradually over a long period of storage of the catheter, even under normal temperature and humidity conditions, potentially resulting in deterioration of the resin over time.

[0021] Here, it is believed that the presence of the hydrolysis inhibitor inhibits the progress of the hydrolysis, and as a result, the deterioration of the resin is inhibited.

[0022] The catheter according to the present invention will be described below with reference to the drawings. In the description of the drawings, the same elements are given the same reference numerals, and duplicate explanations will be omitted. The dimensional proportions in each drawing are exaggerated for the sake of explanation, and may differ from the actual proportions.

[0023] In addition, any combination of two or more of the individual preferred embodiments of the present invention described below is also a preferred embodiment of the present invention and is considered to be disclosed in this specification (i.e., is a lawful basis for amendment).

[0024] FIG. 1 is a diagram showing the overall configuration of a catheter 1 of the present invention.

[0025] 1, the side of the catheter 1 that is inserted into a living body (the left side of FIG. 1) is referred to as the distal end side, the side of the catheter 1 where the hub 30 is disposed is referred to as the proximal end side, and the direction in which the catheter main body 10 of the catheter 1 extends is referred to as the axial direction. Furthermore, in a cross section (cross section perpendicular to the axis) of the catheter main body 10 with the axial direction of the catheter main body 10 as the reference axis, the direction moving away from or approaching the catheter main body 10 is referred to as the "radial direction."

[0026] The catheter 1 has a catheter main body 10 extending in the axial direction, a catheter tip 20 disposed on the distal side of the catheter main body 10, a hub 30 disposed on the proximal side of the catheter main body 10, and a kink-resistant protector (strain relief) 40 disposed between the catheter main body 10 and the hub 30. The catheter main body 10 and the catheter tip 20 are joined to each other.

[0027] The catheter body 10 is formed of a flexible hollow tubular member. A lumen 10H is formed in the catheter body 10 over the entire length of the catheter body 10. The lumen 10H opens at the distal end of the catheter tip 20.

[0028] As shown in Fig. 2, the catheter main body 10 has an inner layer 11 disposed on the inner surface side, an outer layer 12 disposed on the outer periphery of the inner layer 11, a reinforcing material layer 13 disposed inside the outer layer 12, and a hydrophilic lubricating layer 14. In the embodiment shown in Fig. 2, the inner layer 11 and the hydrophilic lubricating layer 14 are disposed to extend to the distal end of the catheter tip 20. Therefore, the inner layer 11 and the hydrophilic lubricating layer 14 are common to the inner layer and the hydrophilic lubricating layer in the catheter tip 20.

[0029] The inner layer 11 is preferably made of a material that provides low friction at least in the portion that comes into contact with a device such as a treatment catheter or a guidewire when the device is inserted into the lumen 10H. This configuration allows the device inserted into the catheter main body 10 to move longitudinally with less sliding resistance, improving operability. Specifically, the inner layer 11 can be made of a fluorine-based resin material such as polytetrafluoroethylene (PTFE).

[0030] The outer layer 12 is preferably made of a material that has kink resistance, suitable pushability, and conformability. Specifically, the material that can be used for the outer layer 12 is a polyamide elastomer and / or polyamide (a polyamide elastomer, a polyamide, or a combination thereof), polyester, a polyester elastomer, a polyurethane elastomer, a polyurethane resin, or a combination thereof.

[0031] The reinforcing material layer 13 has a plurality of reinforcing wires that reinforce the catheter main body 10. Examples of the reinforcing wires include those in a spiral or braided shape. The reinforcing wires are made of a metal such as stainless steel. Specific examples include a stainless steel wire that is flattened and processed into a plate, and then a plurality of approximately 8 to 32 of these wires are used to form a spiral or braided structure (braided body) so that the radial thickness of the catheter main body 10 is thin. The number of reinforcing wires is preferably a multiple of 8 to achieve balanced reinforcement in a tubular shape, but is not limited to this.

[0032] By making the reinforcing wire flat, it receives external stress evenly compared to an ellipse, resulting in consistent physical properties.

[0033] The number of layers constituting the catheter main body 10 and the materials constituting each layer may vary along the longitudinal direction of the catheter main body 10. For example, in order to make the distal end portion of the catheter main body 10 more flexible, the number of layers may be reduced, a more flexible material may be used, a reinforcing material may not be provided in that portion, or an inner layer may be provided all the way to the distal end.

[0034] The catheter is inserted into the body while its position is confirmed under X-ray fluoroscopy. In the present invention, since the catheter tip 20 contains a tungsten-containing compound, which is a radiopaque material, the catheter main body 10 does not necessarily need to contain a radiopaque material. However, a radiopaque material (an X-ray contrast agent) may be blended into the material constituting the outer layer 12. Examples of radiopaque materials that can be used include barium sulfate, bismuth oxide, and tungsten. Furthermore, the radiopaque material need not necessarily be present throughout the entire length of the catheter main body 10, but may be present only in a portion of the catheter main body 10, such as only the distal end or only the catheter tip 20.

[0035] The constituent material of the hydrophilic lubricating layer 14 is not particularly limited, but examples thereof include copolymers of epoxy group-containing monomers such as glycidyl acrylate, glycidyl methacrylate, 3,4-epoxycyclohexylmethyl acrylate, 3,4-epoxycyclohexylmethyl methacrylate, β-methylglycidyl methacrylate, and allyl glycidyl ether with hydrophilic monomers such as N-methylacrylamide, N,N-dimethylacrylamide, and acrylamide; (co)polymers composed of the above-mentioned hydrophilic monomers; cellulose-based polymeric substances such as hydroxypropyl cellulose and carboxymethyl cellulose; polysaccharides, polyvinyl alcohol, methyl vinyl ether-maleic anhydride copolymer, water-soluble polyamide, poly(2-hydroxyethyl (meth)acrylate), polyethylene glycol, polyacrylamide, polyvinylpyrrolidone, and copolymers of polyvinylpyrrolidone and polyurethane described in U.S. Pat. No. 4,100,309 and Japanese Patent Laid-Open No. 59-19582. These hydrophilic lubricating materials may be used alone or in the form of a mixture of two or more kinds.

[0036] A hub 30 is attached (fixed) to the proximal end of the catheter main body 10. The hub 30 has an inner cavity that communicates with the lumen 10H and has a luer taper formed therein.

[0037] The distal end of the catheter main body 10 and the catheter tip 20 can be joined together as a single unit by, for example, heat fusion.

[0038] The hub 30 can be used to insert or remove long objects (linear objects) such as guidewires, catheters (e.g., balloon catheters and stent delivery catheters), endoscopes, ultrasound probes, and temperature sensors, and can also be used to inject various liquids such as contrast agents (X-ray contrast agents), medicinal solutions, and physiological saline. The hub 30 can also be connected to other devices, such as a Y-branch connector. The hub 30 can be made of thermoplastic resins such as polycarbonate, polyamide, polysulfone, and polyarylate.

[0039] The catheter tip and its constituent materials are described below. In this specification, the range "X to Y" includes X and Y and means "X or more and Y or less." Unless otherwise specified, operations and measurements of physical properties are performed at room temperature (20 to 25°C) and a relative humidity of 40 to 50% RH.

[0040] (Catheter Tip) The catheter tip 20 is made of a material that is more flexible than the catheter main body 10. The catheter tip 20 is also called a distal tip, and has the functions of suppressing damage to a biological lumen such as a blood vessel and improving insertability into a stenosis formed in a blood vessel. In Fig. 2, the catheter tip 20 has a tapered shape in which the outer diameter decreases toward the distal end, but the outer diameter may be substantially constant up to the distal end.

[0041] The catheter tip comprises a resin having an ester bond and / or an amide bond (a resin having an ester bond, an amide bond, or a combination thereof), a tungsten-containing compound, and a hydrolysis inhibitor. The catheter tip has X-ray contrast properties due to the inclusion of the tungsten-containing compound. The resin having an ester bond and / or an amide bond, the tungsten-containing compound, and the hydrolysis inhibitor are preferably present in the same layer (tungsten-containing layer (a layer in a catheter tip that contains a tungsten-containing compound is also referred to as a tungsten-containing layer)). The tungsten-containing layer may be a single layer or a multi-layer structure consisting of two or more layers. In the case of a multi-layer structure, the compositions (such as resin type and mixing ratio) may be the same or different. Furthermore, the tungsten-containing compound is preferably dispersed as particles within the resin.

[0042] The catheter tip may be composed of only the tungsten-containing layer, or other functional layers (such as the aforementioned hydrophilic lubricating layer) may be laminated on the inner layer side (lumen side) and / or outer layer side (surface side) of the tungsten-containing layer.

[0043] Examples of resins having an ester bond and / or an amide bond (hereinafter also simply referred to as resins having bonds) include ethylene-vinyl acetate copolymers, polyamides, polyamide elastomers, polyurethane elastomers, polyamideimides, etc. The above resins may be used alone, or two or more may be laminated or blended.

[0044] Among these, the resin having bonds preferably contains a polyamide-based resin because it has high flexibility and little affinity or difference in hardness with adjacent members, more preferably contains polyamide and / or polyamide elastomer (polyamide, polyamide elastomer, or a combination thereof), and even more preferably contains polyamide elastomer. The resin having bonds preferably contains 50% by mass or more (up to 100% by mass), more preferably 80% by mass or more (up to 100% by mass), and even more preferably 100% by mass (consisting of polyamide-based resin). Furthermore, the resin having bonds preferably contains 50% by mass or more (up to 100% by mass), more preferably 80% by mass or more (up to 100% by mass), and even more preferably 100% by mass (consisting of polyamide elastomer).

[0045] In addition, the resin having bonds in the resin constituting the catheter tip is preferably 80% by mass or more (upper limit 100% by mass), more preferably 90% by mass or more (upper limit 100% by mass), and even more preferably 100% by mass (consisting of resin having bonds).Furthermore, the resin having bonds in the resin in the tungsten-containing layer is preferably 80% by mass or more (upper limit 100% by mass), more preferably 90% by mass or more (upper limit 100% by mass), and even more preferably 100% by mass (consisting of resin having bonds).

[0046] A polyamide elastomer is a thermoplastic resin made of a copolymer having hard segments derived from a crystalline polymer with a high melting point and soft segments derived from an amorphous polymer with a low glass transition temperature, and refers to a polymer having an amide bond (-CONH-) in the main chain of the polymer that forms the hard segment. A structural unit having an amide bond (-CONH-) in the main chain of the polymer that forms the hard segment is also called an amide unit of a polyamide elastomer.

[0047] In this specification, the term "amide unit of a polyamide elastomer" refers to a repeating unit derived from an amide bond in a polymer chain of the polyamide elastomer, and the amide unit in the polyamide elastomer is preferably a repeating unit represented by the following formula (1):

[0048]

[0049] In the above formula (1), n ​​is preferably an integer of 2 to 20, and more preferably an integer of 5 to 11. In the examples described later, n is 11.

[0050] Examples of polymers that form soft segments include polyesters and polyethers. Further examples include polyethers such as polyethylene glycol, polypropylene glycol, polytetramethylene ether glycol (PTMG), and polyester polyols, and ABA triblock polyether diols. The polymers that form soft segments may be used alone or in combination of two or more. Furthermore, polyether diamines obtained by reacting ammonia or the like with the terminals of polyethers may be used, and for example, ABA triblock polyether diamines may be used. Polyethers, which are polymers that can form soft segments, can form polyether block amide copolymers in which they are bonded to polyamide blocks, which are hard segments, via ester bonds.

[0051] The content of the soft segment in the polyamide elastomer is preferably from 1 to 50% by mass, more preferably from 10 to 30% by mass.

[0052] In addition to the hard segment and soft segment, the polyamide elastomer may contain a chain extender such as dicarboxylic acid.

[0053] These polyamide elastomers may be used alone or in combination of two or more.

[0054] The weight average molecular weight of the polyamide elastomer is preferably 10,000 to 500,000, more preferably 15,000 to 400,000, and even more preferably 20,000 to 300,000.

[0055] The molecular weight of the polymer according to the present invention can be measured by a known method such as MS spectroscopy, light scattering, liquid chromatography, gas chromatography, or gel permeation chromatography (GPC), and in this specification, the molecular weight is measured by GPC.

[0056] The measurement conditions for the GPC method can be, for example, as follows: (1) Pretreatment: Filtration with a 0.45 μm PTFE cartridge filter (2) Apparatus: HLC-8420GPC (manufactured by Tosoh Corporation) (3) Separation column: TSKgel Super AWM-H (6.0 mm ID x 15 cm) (4) Measurement temperature: 40°C (5) Carrier: hexafluoroisopropanol (+10 mM CF 3 (COONa) (6) Flow rate: 0.3 mL / min (7) Injection volume: 20 μL (8) Detector: differential refractometer (RI detector), polarity = (+) (9) Concentration: 1 mg / mL (10) Molecular weight standard: standard polymethyl methacrylate.

[0057] From the viewpoint of flexibility, the Shore D hardness of the polyamide elastomer that can be used for the catheter tip is preferably 20 to 80, and more preferably 30 to 50. The hardness of the polyamide elastomer is measured using the Shore D hardness according to ISO 868:2003. When multiple types of polyamide elastomers are used, the Shore D hardness of the entire polyamide elastomer is used, taking into account the mass ratio of the polyamide elastomers.

[0058] The polyamide is not particularly limited as long as it is a polymer having an amide bond (—CO—NH—) in the main chain, and is usually produced by polymerization of a lactam or amino acid having a ring structure, or by condensation polymerization of a dicarboxylic acid and a diamine. Homopolyamides are preferably used as polyamides. Monomers that can be polymerized independently include ε-caprolactam, ω-laurolactam, 6-aminocaproic acid, enantholactam, 7-aminoheptanoic acid, 11-aminoundecanoic acid, 12-aminododecanoic acid, 9-aminononanoic acid, and piperidone.

[0059] Furthermore, when polycondensing a dicarboxylic acid and a diamine, examples of the dicarboxylic acid include adipic acid, sebacic acid, dodecanedicarboxylic acid, glutaric acid, terephthalic acid, 2-methylterephthalic acid, isophthalic acid, naphthalenedicarboxylic acid, etc. Examples of the diamine include tetramethylenediamine, hexamethylenediamine, nonamethylenediamine, decamethylenediamine, undecamethylenediamine, dodecamethylenediamine, paraphenylenediamine, metaphenylenediamine, etc.

[0060] Examples of polyamides include nylon 4, 6, 7, 8, 11, 12, 6.6, 6.9, 6.10, 6.11, 6.12, 6T, 6 / 6.6, 6 / 12, 6 / 6T, 6T / 6I, etc. The polyamides may be used singly or in combination of two or more.

[0061] The polyamide may be end-capped with a carboxylic acid, an amine, etc. Examples of the carboxylic acid include aliphatic monocarboxylic acids such as caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, and behenic acid. Examples of the amine include aliphatic primary amines such as hexylamine, octylamine, decylamine, laurylamine, myristylamine, palmitylamine, stearylamine, and behenylamine.

[0062] The weight average molecular weight of the polyamide is preferably 10,000 to 500,000, more preferably 15,000 to 400,000, and even more preferably 20,000 to 300,000.

[0063] The content of the resin having a bond relative to the total amount (100% by mass) of the resin having a bond, the tungsten-containing compound, and the hydrolysis inhibitor is appropriately set in consideration of X-ray contrast properties, flexibility, moldability, and the like, and may be, for example, 10 to 90% by mass, or may be 20 to 70% by mass.

[0064] (Tungsten-containing compound) The catheter tip contains a tungsten-containing compound as an X-ray opaque material. Examples of the tungsten-containing compound include simple metal tungsten and tungsten carbide. The tungsten-containing compound may be used alone or in combination of two or more.

[0065] The tungsten-containing compound is preferably in the form of particles. Here, for example, tungsten carbide particles refer to particles in which tungsten carbide is the main component (the component with the largest amount) (preferably 80 mass % or more, 90 mass % or more, 95 mass % or more, or 98 mass % or more of the main component), and the tungsten carbide usually contains uncarburized tungsten.

[0066] The tungsten-containing compound is preferably tungsten powder (particles). In addition to tungsten (W) as the main component (preferably 80 mass % or more, 90 mass % or more, 95 mass % or more, 98 mass % or more), tungsten powder usually contains oxygen (combined with tungsten) and a very small amount of tungsten oxide (WO X’ (X'≒2), WO X (2<X<3)), iron (Fe), molybdenum (Mo), etc.

[0067] The average particle size of the tungsten powder is preferably 0.5 to 30 μm, more preferably 1 to 10 μm, and even more preferably 2 to 4 μm. The average particle size is the volume average particle size measured by dynamic light scattering, but is not limited to this.

[0068] Furthermore, various types of tungsten powder are commercially available, and in the present invention, these commercially available products can be preferably used.

[0069] The content of the tungsten-containing compound is preferably 10 to 90 mass %, more preferably 20 to 80 mass %, and even more preferably 50 to 80 mass %, based on the total amount of the bond-containing resin and the tungsten-containing compound, and may be more than 50 mass % to 80 mass % or less, or may be 60 to 80 mass %. When the content of the tungsten-containing compound is within the above range, excellent contrast properties and flexibility are achieved.

[0070] (Hydrolysis inhibitor) As the hydrolysis inhibitor, conventionally known ones can be used, for example, compounds that react with the carboxyl group terminal of the decomposition product to bond, specific examples of which include compounds containing functional groups such as a carbodiimide group, an epoxy group (for example, a glycidyl ester compound, a glycidyl ether compound, etc.), an oxazoline group (for example, a bisoxazoline compound, etc.), etc. Among these, from the viewpoint of the hydrolysis inhibitory effect, it is preferable that the hydrolysis inhibitor be a carbodiimide group-containing compound.

[0071] The carbodiimide group-containing compound is a compound having a carbodiimide group (—N═C═N—) in the molecule. The carbodiimide group-containing compound is preferably polyfunctional (having two or more carbodiimide groups in the molecule).

[0072] The carbodiimide group-containing compound is preferably a cyclic carbodiimide or a polycarbodiimide. Of these, the carbodiimide group-containing compound is preferably a polycarbodiimide, as this will more effectively achieve the effects of the present invention.

[0073] Examples of polycarbodiimides include aromatic polycarbodiimide compounds, aliphatic polycarbodiimide compounds, and alicyclic polycarbodiimide compounds. Here, polycarbodiimides are usually linear. An aromatic polycarbodiimide compound is a polycarbodiimide compound that has an aromatic ring in the molecule and may or may not have an aliphatic ring. An aliphatic polycarbodiimide compound is a polycarbodiimide compound that has neither an aromatic ring nor an aliphatic ring in the molecule. An alicyclic polycarbodiimide compound is a polycarbodiimide compound that has an aliphatic ring in the molecule but does not have an aromatic ring. Among these, from the viewpoint of storage stability, aromatic polycarbodiimide compounds and / or alicyclic polycarbodiimide compounds are preferred, and alicyclic polycarbodiimide compounds are more preferred, and polycarbodiimide compounds that are cyclic may also be used.

[0074] Specific examples of polycarbodiimides include those obtained by subjecting diisocyanates to a decarboxylation condensation reaction. The diisocyanate may be, for example, a linear or alicyclic aliphatic diisocyanate compound, an aromatic diisocyanate compound, or a heterocyclic diisocyanate compound. These may be used alone or in combination of two or more. Specific examples include linear aliphatic diisocyanates such as tetramethylene diisocyanate, hexamethylene diisocyanate, dodecamethylene diisocyanate, and 2,2,4-trimethylhexamethylene diisocyanate; and alicyclic diisocyanates such as 1,4-bis(isocyanatomethyl)cyclohexane, 2,2-bis(4-isocyanatocyclohexyl)propane, isophorone diisocyanate, and dicyclohexylmethane-4,4'-diisocyanate. Diisocyanates include aliphatic diisocyanates containing an aromatic ring such as 1,3-bis(2-isocyanato-2-propyl)benzene, and aromatic isocyanates such as toluene-2,4-diisocyanate, 2,2'-diphenylmethane diisocyanate, 2,4'-diphenylmethane diisocyanate, 4,4'-diphenylmethane diisocyanate, and 2,4,6-triisopropylbenzene-1,3-diyl diisocyanate. These may be used alone or in combination of two or more.

[0075] In terms of storage stability, polycarbodiimides in which the terminal isocyanate groups are blocked with a blocking agent are preferred. Examples of blocking agents include compounds having active hydrogen that reacts with isocyanate groups, or compounds having an isocyanate group. Examples include monoalcohols, monocarboxylic acids, monoamines, and monoisocyanates each having one substituent selected from a carboxy group, an amino group, and an isocyanate group.

[0076] Examples of cyclic carbodiimides include cyclic carbodiimide compounds represented by formula (i) disclosed in WO 2010 / 071211 (specifically, the cyclic carbodiimide compounds described on pages 13 to 15, and cyclic carbodiimide compounds represented by formula (i) disclosed in U.S. Patent Application Publication No. 2011 / 251384 (pages 4 to 6), the disclosure of which is incorporated by reference), and cyclic carbodiimide compounds represented by formula (i) described in JP 2016-65001 A (specifically, the cyclic carbodiimide compounds described on pages 10 to 11).

[0077] The method for adding and mixing the hydrolysis inhibitor with the resin is not particularly limited, and mixing may be performed by dry blending, or the resin may be in a solution or melt state and the hydrolysis inhibitor (e.g., a carbodiimide group-containing compound) may be kneaded with the resin. A solvent may also be used during kneading. Examples of the solvent that can be used include hydrocarbon solvents, ketone solvents, ester solvents, ether solvents, halogenated solvents, and amide solvents.

[0078] The amount of the hydrolysis inhibitor added is preferably 2 parts by mass or less, more preferably 0.01 to 2 parts by mass, and even more preferably 0.05 to 1 part by mass, per 100 parts by mass of the resin having bonds. By adding the amount of the hydrolysis inhibitor within this range, resin degradation is effectively suppressed and the resin properties are little affected.

[0079] The catheter tip 20 may be provided with a hydrophilic lubricating layer that provides surface lubricity when wet (hydrophilic lubricating layer 14 in FIG. 2), which is disposed radially outward of the tungsten-containing layer.

[0080] The constituent materials of the hydrophilic lubricating layer are not particularly limited, but examples thereof include copolymers of epoxy group-containing monomers such as glycidyl acrylate, glycidyl methacrylate, 3,4-epoxycyclohexylmethyl acrylate, 3,4-epoxycyclohexylmethyl methacrylate, β-methylglycidyl methacrylate, and allyl glycidyl ether with hydrophilic monomers such as N-methylacrylamide, N,N-dimethylacrylamide, and acrylamide; (co)polymers composed of the above hydrophilic monomers; cellulose-based polymers such as hydroxypropyl cellulose and carboxymethyl cellulose; polysaccharides, polyvinyl alcohol, methyl vinyl ether-maleic anhydride copolymers, water-soluble polyamides, poly(2-hydroxyethyl (meth)acrylate), polyethylene glycol, polyacrylamide, polyvinylpyrrolidone, and copolymers of polyvinylpyrrolidone and polyurethane described in U.S. Pat. No. 4,100,309 and Japanese Patent Laid-Open No. 59-19582. These hydrophilic lubricating materials may be used alone or in the form of a mixture of two or more.

[0081] The catheter tip 20 may also be provided with an inner layer (inner layer 11 in FIG. 2 ) so that at least the portion that comes into contact with a device such as a treatment catheter or a guidewire will have low friction when the device is inserted into the lumen 10H. The inner layer is preferably made of a material that will have low friction at least in the portion that comes into contact with the device when the device is inserted into the lumen 10H. Specifically, the inner layer may be made of a fluorine-based resin material such as polytetrafluoroethylene (PTFE).

[0082] The catheter tip may contain pigments or dyes that produce white, black, blue, red, or yellow colors, or mixtures thereof. Examples of such pigments or dyes include carbon black, activated carbon, graphite, carbon nanotubes, fullerenes, titanium oxide, and condensed polycyclic organic pigments such as cyanine pigments, nickel dithiolene pigments, squarium pigments, naphthoquinone pigments, diimmonium pigments, azo organic pigments, phthalocyanine pigments, naphthalocyanine pigments, and azulenocyanine pigments.

[0083] The catheter tip may also have a reinforcing member made of SUS or the like disposed in the above-mentioned material. The reinforcing member may be in the form of a coil or a blade.

[0084] The effects of the present invention will be explained using the following examples and comparative examples. However, the technical scope of the present invention is not limited to the following examples. In the following examples, unless otherwise specified, operations were performed at room temperature (25°C). Furthermore, unless otherwise specified, "%" and "parts" mean "% by mass" and "parts by mass", respectively.

[0085] [Preparation of Dumbbell-Shaped Test Pieces] [Example 1] 30 parts by mass of polyamide elastomer (Shore D hardness 40, weight-average molecular weight (Mw) approximately 40,000) was mixed with 70 parts by mass of tungsten particles (average particle size 3.0 μm, W of 99.9% or more), and 0.3 parts by mass of an alicyclic polycarbodiimide compound, a carbodiimide group-containing compound, as a hydrolysis inhibitor. Press molding was carried out using a 20 ton manual hydraulic heating press at a set temperature of 200°C. The thickness of the molded product was 1.9 to 2.1 mm. The molded press sheet was punched out according to JIS K 7161-2:2014 5A to obtain dumbbell-shaped test pieces.

[0086] Example 2 A dumbbell-shaped test piece was prepared in the same manner as in Example 1, except that a cyclic carbodiimide compound, which is a carbodiimide group-containing compound, was used as the hydrolysis inhibitor instead of the alicyclic polycarbodiimide compound.

[0087] Comparative Example 1 A dumbbell-shaped test piece was prepared in the same manner as in Example 1, except that no carbodiimide group-containing compound was used as the hydrolysis inhibitor.

[0088] [Load Test] The dumbbell-shaped test pieces prepared in the Examples and Comparative Examples were subjected to high-temperature and high-humidity conditions. Specifically, the dumbbell-shaped test pieces were subjected to a load test for a total of seven cycles (one week), with the conditions shown in Table 3 below being defined as one cycle (24 hours).

[0089]

[0090] [Tensile Test] According to JIS K 7161-1:2014, a tensile test was performed on the dumbbell-shaped test pieces of Examples 1 and 2 and Comparative Example 1 before and after the load test.

[0091] <Test conditions> Distance between grippers: 50 mm Distance between gauge lines: 20 mm Test speed: 100 mm / min.

[0092] The survival rate was calculated using the following formula to indicate durability. A higher survival rate indicates higher durability. Here, the breaking stroke length refers to the value obtained by subtracting the gauge length before the test from the gauge length after breaking.

[0093]

[0094]

[0095] As a result of the tensile test, the dumbbell-shaped test piece of Comparative Example 1 had a survival rate of about 7% before and after the load test, whereas the dumbbell-shaped test pieces of Examples 1 and 2 had a survival rate of 10% or more before and after the load test, which was higher than that of Comparative Example 1. From this result, it was confirmed that the dumbbell-shaped test piece of Example 1 has higher durability than the dumbbell-shaped test piece of Comparative Example 1.

[0096] This application is based on Japanese Patent Application No. 2023-081659, filed on May 17, 2023, the disclosure of which is hereby incorporated by reference in its entirety.

[0097] 1 Catheter, 10 Catheter body, 30 Hub, 20 Catheter tip, 40 Kink-resistant protector (strain relief).

Claims

1. A catheter tip comprising a resin having an ester bond and / or an amide bond, a tungsten-containing compound, and a hydrolysis inhibitor.

2. The catheter tip of claim 1, wherein the hydrolysis inhibitor is a carbodiimide group-containing compound.

3. The catheter tip according to claim 1 or 2, wherein the content of the tungsten-containing compound is 10 to 90 mass % based on the total amount of the resin and the tungsten-containing compound.

4. The catheter tip according to claim 1 or 2, wherein the resin having an ester bond and / or an amide bond includes a polyamide resin.

5. The catheter tip of claim 1 or 2, wherein the tungsten-containing compound is dispersed as particles within the resin.

6. A catheter comprising a catheter tip according to claim 1 or 2.

Citation Information

Patent Citations

  • Liquid refining system by magnetic resonance

    JP1984019582A

  • Cyclic carbodiimide compound

    JP2016065001A

  • Plug, packaging container with plug, and manufacturing method for the same

    JP2023081659A

  • Cyclic carbodiimide compounds

    US20110251384A1

  • Coated substrate having a low coefficient of friction hydrophilic coating and a method of making the same

    US4100309A